Carcinoma,_hepatocellular

Combination Therapy with Bisoprolol and Tissue Protective Molecule ARA 284 Is Cardio-Protective and Improves Survival in Experimental Cancer Cachexia.

BACKGROUND

Cancer cachexia is a serious condition during the last stages of the disease, which is characterized by the loss of muscle and fat mass in patients with cancer. There are no effective treatments for cancer cachexia, and new treatment interventions...

🗓️ 2026-06-25
Read MoreCombination Therapy with Bisoprolol and Tissue Protective Molecule ARA 284 Is Cardio-Protective and Improves Survival in Experimental Cancer Cachexia.

Prevalence and Prognostic Impact of the Coexistence of Cachexia and Sarcopenia in Patients With Chronic Liver Diseases.

BACKGROUND

Cachexia and sarcopenia are prevalent, inflammation-linked syndromes in chronic liver disease that worsen outcomes. To our knowledge, their coexistence in a single chronic liver disease cohort has not been systematically examined. In this study, we evaluated the prevalence, clinical features...

🗓️ 2026-05-06
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MorePrevalence and Prognostic Impact of the Coexistence of Cachexia and Sarcopenia in Patients With Chronic Liver Diseases.

GFRAL-Fc disarms GDF15 to reprogram tumor immunity and amplify PD-1 efficacy in hepatocellular carcinoma.

BACKGROUND

Checkpoint inhibitors have revolutionized hepatocellular carcinoma (HCC) treatment, yet their efficacy remains limited in advanced stages, with suboptimal objective response rates. Growth differentiation factor 15 (GDF15), a dual-functional cytokine implicated in tumor progression and immunosuppression, represents a promising therapeutic target....

🗓️ 2025-10-15
Read MoreGFRAL-Fc disarms GDF15 to reprogram tumor immunity and amplify PD-1 efficacy in hepatocellular carcinoma.

Comment on "Myosteatosis and Muscle Loss Impact Liver Transplant Outcomes in Male Patients With Hepatocellular Carcinoma" by Lu et al.-The Authors' Reply.

🗓️ 2025-04-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreComment on "Myosteatosis and Muscle Loss Impact Liver Transplant Outcomes in Male Patients With Hepatocellular Carcinoma" by Lu et al.-The Authors' Reply.

A fluorescent aptasensor for deoxynivalenol detection based on Nb.BbvCI-assisted targeted-responsive three-way junctions integrated DNA walking machine.

Deoxynivalenol (DON) contamination in cereals is a widespread issue with global implications, necessitating the development of efficient detection methods. Here, a fluorescent aptasensor integrating target-responsive DNA three-way junction (TWJ) and DNA walking machine was developed to detect DON. The DON-specific...

🗓️ 2024-12-06
📰 Publication: Food Chemistry
Read MoreA fluorescent aptasensor for deoxynivalenol detection based on Nb.BbvCI-assisted targeted-responsive three-way junctions integrated DNA walking machine.

Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213).

Cancer cachexia can impact prognosis, cause resistance to anticancer treatments and affect the tolerability of treatments. This study aims to identify hepatocellular carcinoma (HCC) with cachexia by characterizing longitudinal body composition (BC) trajectories. This longitudinal, multicentre cohort study included unresectable...

🗓️ 2024-11-27
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreLongitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213).

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!